A decade after DSHEA, we are proud of our contributions to the nutraceutical revolution. We pioneered the introduction of several healthful botanical extracts, phytochemicals and nutritional fine chemicals to the global marketplace and worked with standards agencies to develop quality criteria and monographs for these ingredients. Along the way, we found innovative applications for several traditional raw materials, which are now patented or patent pending both in the U.S. and internationally.

Encouraged by the Nutritional industry, Sabinsa continues to invest in research on these products and continues to cover the usage of BioPerine® and ForsLean® with additional U.S., European and International patents.

From 1996 until today, many companies have taken our science (and our Intellectual Property), and ascribed it to generic material in their formulas. Such activities continue in light of our open efforts to educate these companies, and the industry, on intellectual property rights and patent infringement. It is against this background that Sabinsa made the decision to seek legal protection and remedies for our intellectual property and patent rights.

At no time have we intended to harass the industry that provides the very basis of our existence. Again, it is the few companies that continue to ignore the property rights of others, that infringe on intellectual property without regard to the owners, that Sabinsa has decided to take legal action against to protect our rights.

In the months and years ahead, Sabina’s commitment to the innovation of new products will continue, and we seek your understanding of the legal path we may be compelled to follow at times to protect our intellectual property rights.

As always, we will continue to foster the tradition of quality and innovation that you have come to expect from SABINSA, in the current year and in the years to come.
I take this opportunity to wish you all a very Happy and Healthy 2004

High levels of low density lipoprotein (LDL) cholesterol are particularly correlated with atherosclerosis and cardiovascular disease, based on evidence from clinical studies and epidemiological analysis. Multiple risk factors for cardiovascular disease commonly recognized in current medical literature include: age (over 45 for men and postmenopause for women), high blood pressure, diabetes mellitus, Syndrome X (characterized by central type of obesity, elevated blood triglycerides, hypertension and abnormal glucose metabolism), genetic predisposition, serum HDL levels <40 mg/dL, serum lipoprotein (a) or Lp(a) levels above 20 mg/dL, serum homocysteine levels >10 nmol/L, the ratio of VLDL cholesterol/triglycerides>0.3, high concentrations of blood coagulation (clotting) factors, insulin resistance with hyperinsulinemia, midsection obesity, high levels of inflammatory compounds like C-reactive protein, high white blood and red blood cells counts, deficiency of antioxidant vitamins, cigarette smoking, alcohol abuse, infection with Chlamydia and gum disease causing Porphyromonas gingivalis.

A healthy lifestyle with appropriate diet and exercise regimens in combination with nutritional support with phytonutrients, mineral nutrients and vitamins is beneficial
in lowering modifiable risk factors. Nutraceuticals that support healthy cardiac muscular functions, circulation and serum lipid levels, are beneficial to cardiovascular health.

These may be combined with nutrients that provide antioxidant support, blood sugar support, anti-inflammatory support, digestive support, and immune support, to present comprehensive formulations to support cardiovascular health.

Ingredients in such formulations could include Gugulipid® (Commiphora mukul extract), Policosanol, Inula racemosa extract, Terminalia arjuna extract, CoQ10, Ginger extract, Curcumin C3Complex® and bioavailable sources of magnesium, vanadium and selenium. Bioperine® added to such formulations would help enhance the absorption and bioavailability of these nutrients.

Contact Sabinsa Corporation for details on natural ingredients and formulation guidelines for cardiovascular support.

The role of quality control starts from the stage of identification of raw materials.

At our facilities, all herbal raw materials are procured from approved vendors after conducting vendor audit, to ensure the supply of consistent quality raw materials. We scrutinize the documentation of their quality system and storage facilities. In most cases a second supplier is also identified.

Firstly, botanicals are authenticated for genus and species, by a qualified botanist. An in-house herbarium facilitates the comparison of raw materials at any given time.

Once our botanist approves the herbal raw material, it is subjected to experimental extraction to test the yield, identity and quantity of actives, using sophisticated instrumentation (HPLC, GC, UV, IR). Raw materials will be used for commercial extraction only if they pass these tests, and conform to our specifications.

A schematic representation of the above steps is presented: